Physician profile
Barry D Crabtree
NPI 1447224894
$2,951.31
in general payments reported to CMS, 2019-2025
21 companies · $566 in 2025
The $566 reported for 2025 was more than what 95% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $391 · 2020: $75.06 · 2021: $288 · 2022: $414 · 2023: $407 · 2024: $811 · 2025: $566.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,784.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,783.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $732.20 | 2021-2025 | Qelbree, Qelbree |
| Corium, LLC | $467.54 | 2023-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $284.54 | 2019-2024 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $224.84 | 2019-2022 | |
| Glaxosmithkline, LLC. | $208.42 | 2019-2025 | Pediarix, Bexsero, Rotarix |
| Merck Sharp & Dohme LLC | $154.43 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Pfizer INC. | $144.64 | 2019-2025 | |
| Sanofi Pasteur INC. | $118.74 | 2021-2025 | |
| Genentech USA, INC. | $104.00 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $100.04 | 2025 | Jornay Pm |
| Tris Pharma INC | $94.42 | 2019-2022 | |
| Seqirus USA INC | $83.22 | 2021-2023 | Flucelvax Quadrivalent |
| Verrica Pharmaceuticals INC. | $43.30 | 2024 | Ycanth |
| Medtronic, INC. | $37.02 | 2024 | Intellis Adaptivestim |
| Sanofi-Aventis U.S. LLC | $35.63 | 2024-2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $33.70 | 2019 | |
| Arbor Pharmaceuticals, INC. | $20.04 | 2019 | |
| Abbvie INC. | $19.29 | 2023 | Qulipta |
| Alexion Pharmaceuticals, INC. | $16.71 | 2020 | |
| Novo Nordisk INC | $16.41 | 2023 | Wegovy |
| Adlon Therapeutics L.P. | $12.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Crabtree listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.